Navigation Links
CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
Date:10/3/2007

COSTA MESA, Calif., Oct. 3 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today the appointment of George C. Carpenter IV as President. Len Brandt, Chairman and CEO, who previously held the title of President, will continue as the Company's chief executive.

A 20-year veteran of the health services industry, Mr. Carpenter was most recently President and CEO of Work WellSystems, Inc., a national physical medicine firm that manages occupational health programs for Fortune 500 employers. Prior to that, Mr. Carpenter was CEO of CORE, Inc., a publicly- traded market leader in integrated health and disability management.

As president of CNS Response, Mr. Carpenter will be focused on the commercialization of the Company's Referenced-EEG(SM) (rEEG(SM)) platform to improve the success of behavioral therapies for patients. rEEG(SM) is a patented system that uses electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical database to characterize features of brain function underlying a broad range of psychiatric syndromes.

"It's great to have George's leadership and experience as the Company's President," stated Len Brandt, Chairman and CEO of CNS Response, Inc. "As a pioneer in driving adoption of new and innovative technologies in under-served markets, Mr. Carpenter will now focus on the commercialization of our rEEG(SM) among psychiatrists, patients and payors in advancing personalized medicine in behavioral disorders. His experience at high-growth, innovative healthcare companies adds tremendous value to CNS Response, and we are excited to have him join our management team."

Of particular note, Mr. Carpenter founded CORE, Inc. and served as its Chairman and CEO from 1990 until its acquisition by Assurant, Inc. in 2001. Utilizing its proprietary WorkAbility database, CORE became a market leader in integrated health and disability management. CORE, Inc. was established by Mr. Carpenter after leading the management buyout of the division of Baxter Healthcare where he was Vice President, Operations.

"Analogous to our work at CNS Response, CORE's unique database allowed vastly improved management of medical disability for large employers and payors. That background should help in our mission to improve management of behavioral healthcare, particularly with employers and payors," commented Horace Hertz, CFO of CNS Response.

Mr. Carpenter, President of CNS Response, remarked, "I have commercialized a number of technologies in health care, but have never seen such a potentially industry-changing opportunity. The implications of a technology that helps doctors prescribe the right medication for the right patients, even the most treatment-resistant, are enormous for patients, providers and payors. I look forward to working with Len and his team to make this happen."

About CNS Response

CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(SM) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG(SM) to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contacts:

Investor Relations:

Sara Ephraim

(646) 536-7002

sephraim@theruthgroup.com

Media:

Janine McCargo / Jason Rando

(646) 536-7033 / 7025

jmccargo@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE CNS Response, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. George Bush pledges 200 million dollars for AIDS relief
2. Arsenic May Have Been Responsible For The Madness Of King George III Of England
3. Study Unveils New Insight To The Madness Of King George III
4. Investigation into the Poor Hospital Facility That Led To the Death of George Cook
5. Georgetown University Heads Alternative Tobacco Project
6. Epidural can affect the fetal head position
7. The ideal composition of intravenous lipid emulsion
8. Robotic ovarian transposition helps cancer patient deliver baby
9. Queensland Opposition not happy over hiring consultancy
10. Link between position and sense of smell revealed
11. Opposition: Government turned a deaf ear to warnings about dwindling health care services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid ... Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and ... regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... share of all holidays (IBT World Travel Trends Report). As travelers visit both ... a range in temperatures, and prolonged sun exposure. In response, the outdoor industry ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: